017 Lerna Biopharma: Treating Cirrhosis via Regeneration

One North Stories

This is One North Stories, an A*START CENTRAL Podcast

Kathy He joins to share about Lerna Biopharma (formerly known as Cargene Therapeautics). Lerna is a 3 year old biotech founded out of the Genome Institute of Singapore (GIS), A*STAR. They are leveraging Small molecule RNA (SiRNA) technology to treat liver disease through regeneration, especially cirrhosis of the liver which is considered as untreatable. Lerna is preclinical, having tested on multiple animal models and now preparing to go clinical.

Kathy joined as CEO approximately 1 year ago. She chose Singapore and Lerna, wanting to build on the research of Torsten Wuestefeld and team of GIS. They have an in vivo functional genomic screening platform and found master regulators of liver regeneration. Kathy has the goal of building Lerna into a global biotech plus the current and next generation of bio- pharma- leaders and executives for Singapore’s global aspiration.

Learn more about Lerna, Kathy and the great work they are doing:

https://www.linkedin.com/company/lerna-biopharma/

https://www.linkedin.com/in/kathy-h-21591b3/

Thank you for listening. If you like what you’ve heard, please subscribe and review us wherever you get your podcasts.

Check out A*START CENTRAL at:

https://www.a-star.edu.sg/enterprise/innovation-platforms/a-startcentral

https://sg.linkedin.com/company/astartcentral

If you have future episode ideas, segments ideas or want to partner with us on this exciting journey, please get in touch: [e-mail]